Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin
News
News
It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining.
Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals (ASX:SUD) was up 36% – but both on no news.
The next cab off the ranks was Medibio Limited (ASX:MEB) rising 29% off the back of a newsletter to shareholders detailing the company’s plans to launch its consumer app in October.
CEO and managing director Claude Solitario said the algorithm development for its depressive burden software, MEB-001 and the corporate mental wellness offering ilumen are both “progressing very well.”
The company is also waiting for an FDA meeting about MEBSleep to clear the path for a 60-70 patient, multi-centre pivotal validation trial.
Both up 25% were Chimeric Therapeutics (ASX:CHM) after appointing Dr George Matcham as non-executive director, and Atomo Diagnostics (ASX:AT1) on the news that Access Bio received FDA clearance for its COVID-19 antibody test late last month.
Alterity Theraputics (ASX:ATH) was up 24% after announcing the grant of a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s, and gaining 23% was Pharmaxis (ASX:PXS) – which sold distribution rights in Australia, New Zealand (and several Asian territories) for its Bronchitol® (cystic fibrosis) and Aridol® (asthma) products to a subsidiary of BTC health (ASX:BTC).
Here’s a table showing how ASX-listed healthcare stocks have been performing.
Code | Company | Price | %Yr | %2WK | MktCap |
---|---|---|---|---|---|
BOT | Botanix Pharma Ltd | 0.088 | 100 | 38 | $ 84,663,360.44 |
SUD | Suda Pharmaceuticals | 0.068 | 123 | 36 | $ 33,657,399.02 |
MEB | Medibio Limited | 0.009 | 29 | 29 | $ 16,155,553.48 |
CHM | Chimeric Therapeutic | 0.345 | 73 | 25 | $ 68,891,660.25 |
AT1 | Atomo Diagnostics | 0.1875 | -47 | 25 | $ 79,694,615.72 |
ATH | Alterity Therap Ltd | 0.036 | -14 | 24 | $ 86,647,484.81 |
TD1 | Tali Digital Limited | 0.038 | 46 | 23 | $ 35,412,419.98 |
PXS | Pharmaxis Ltd | 0.087 | 16 | 23 | $ 39,395,702.27 |
ANP | Antisense Therapeut. | 0.22 | 165 | 22 | $ 132,129,558.89 |
BIT | Biotron Limited | 0.061 | -53 | 22 | $ 41,414,030.07 |
ARX | Aroa Biosurgery | 1.23 | 64 | 20 | $ 368,818,235.98 |
UBI | Universal Biosensors | 0.935 | 356 | 20 | $ 162,572,030.25 |
NYR | Nyrada Inc. | 0.34 | 45 | 19 | $ 40,557,939.51 |
VTI | Vision Tech, Inc | 1.28 | -33 | 19 | $ 31,080,682.50 |
CGS | Cogstate Ltd | 1.4 | 229 | 17 | $ 239,383,663.40 |
NEU | Neuren Pharmaceut. | 1.595 | 18 | 16 | $ 183,372,972.80 |
DVL | Dorsavi Ltd | 0.03 | 1 | 15 | $ 10,878,909.73 |
RHT | Resonance Health | 0.17 | 3 | 13 | $ 82,953,356.58 |
SCU | Stemcell United Ltd | 0.017 | 13 | 13 | $ 17,736,451.19 |
AVE | Avecho Biotech Ltd | 0.018 | 157 | 13 | $ 33,050,097.47 |
GTG | Genetic Technologies | 0.009 | 38 | 13 | $ 81,150,540.69 |
AHC | Austco Healthcare | 0.14 | 77 | 12 | $ 38,365,508.39 |
PTX | Prescient Ltd | 0.25 | 291 | 11 | $ 160,263,264.00 |
EYE | Nova EYE Medical Ltd | 0.32 | -12 | 10 | $ 47,416,425.54 |
CBL | Control Bionics | 0.66 | 10 | 10 | $ 33,646,660.99 |
GSS | Genetic Signatures | 1.285 | -49 | 9 | $ 178,634,057.50 |
OSL | Oncosil Medical | 0.065 | -50 | 8 | $ 51,029,970.82 |
OVN | Oventus Medical Ltd | 0.105 | -64 | 8 | $ 23,689,200.43 |
VHT | Volpara Health Tech | 1.19 | -20 | 8 | $ 296,551,795.58 |
MMJ | MMJ Group Hlds Ltd | 0.084 | -15 | 8 | $ 19,086,180.76 |
IVX | Invion Ltd | 0.015 | 50 | 7 | $ 83,093,134.43 |
OSP | Osprey Med Inc | 0.015 | -66 | 7 | $ 35,920,923.89 |
ZLD | Zelira Therapeutics | 0.048 | -14 | 7 | $ 57,135,502.37 |
CAN | Cann Group Ltd | 0.41 | -56 | 6 | $ 113,943,919.18 |
HXL | Hexima | 0.165 | -46 | 6 | $ 21,065,171.58 |
MX1 | Micro-X Limited | 0.34 | 152 | 6 | $ 158,597,100.30 |
SOM | SomnoMed Limited | 2.44 | 82 | 6 | $ 201,105,135.45 |
ADR | Adherium Ltd | 0.018 | -33 | 6 | $ 34,011,729.78 |
CAJ | Capitol Health | 0.365 | 49 | 6 | $ 385,536,567.00 |
BD1 | Bard1 Life Sciences | 1.915 | 113 | 6 | $ 148,104,922.75 |
OPT | Opthea Limited | 1.35 | -46 | 5 | $ 491,404,957.40 |
4DX | 4Dmedical Limited | 1.315 | 78 | 5 | $ 265,240,970.24 |
IPD | Impedimed Limited | 0.105 | 38 | 5 | $ 164,339,614.89 |
RAP | Resapp Health Ltd | 0.044 | -73 | 5 | $ 36,945,474.31 |
OSX | Osteopore Limited | 0.475 | -27 | 4 | $ 37,067,955.00 |
PAB | Patrys Limited | 0.052 | 336 | 4 | $ 90,979,845.25 |
APH | AP Hemp Ltd | 0.405 | 238 | 4 | $ 32,092,256.70 |
BXN | Bioxyne Ltd | 0.028 | 155 | 4 | $ 17,924,071.14 |
TLX | Telix Pharmaceutical | 5.69 | 272 | 3 | $ 1,560,193,680.32 |
MDR | Medadvisor Limited | 0.305 | -47 | 3 | $ 113,211,191.70 |
TRU | Truscreen | 0.068 | 0 | 3 | $ 23,586,306.45 |
PIQ | Proteomics Int Lab | 0.975 | 132 | 3 | $ 105,205,875.00 |
AC8 | Auscann Grp Hlgs Ltd | 0.1075 | -28 | 2 | $ 48,460,182.10 |
DOC | Doctor Care Anywhere | 0.88 | 10 | 2 | $ 157,699,453.12 |
PAA | Pharmaust Limited | 0.091 | -60 | 2 | $ 28,822,422.72 |
EPN | Epsilon Healthcare | 0.1325 | -56 | 2 | $ 25,051,903.37 |
KZA | Kazia Therapeutics | 1.325 | 163 | 2 | $ 178,282,721.11 |
NTI | Neurotech Intl | 0.056 | 409 | 2 | $ 39,021,871.06 |
AGH | Althea Group | 0.34 | -1 | 1 | $ 90,518,871.30 |
M7T | Mach7 Tech Limited | 1.03 | 8 | 1 | $ 233,977,639.50 |
JHC | Japara Healthcare Lt | 1.2475 | 147 | 0 | $ 334,059,160.00 |
ONT | 1300 Smiles Limited | 7.1 | 39 | 0 | $ 168,116,526.40 |
1ST | 1St Group Ltd | 0.021 | -38 | 0 | $ 8,916,954.96 |
ACR | Acrux Limited | 0.14 | -7 | 0 | $ 39,662,755.16 |
ATX | Amplia Therapeutics | 0.225 | 105 | 0 | $ 28,084,801.50 |
ALT | Analytica Limited | 0.0025 | 0 | 0 | $ 11,534,502.82 |
AHK | Ark Mines Limited | 0.034 | 0 | 0 | $ 1,778,919.95 |
CDY | Cellmid Limited | 0.06 | -54 | 0 | $ 11,245,833.60 |
CMP | Compumedics Limited | 0.4 | 0 | 0 | $ 72,636,808.68 |
DXB | Dimerix Ltd | 0.22 | -41 | 0 | $ 42,569,848.86 |
EXL | Elixinol Wellness | 0.13 | -30 | 0 | $ 40,958,210.02 |
ICS | ICSGlobal Limited | 2.19 | 12 | 0 | $ 23,047,601.61 |
IMC | Immuron Limited | 0.16 | -37 | 0 | $ 36,359,455.36 |
LCT | Living Cell Tech. | 0.014 | -7 | 0 | $ 8,000,173.73 |
MDC | Medlab Clinical Ltd | 0.16 | 7 | 0 | $ 54,748,107.36 |
MXC | Mgc Pharmaceuticals | 0.04 | 82 | 0 | $ 94,737,878.93 |
PSQ | Pacific Smiles Grp | 2.74 | 77 | 0 | $ 438,850,329.50 |
PCK | Painchek Ltd | 0.061 | -49 | 0 | $ 66,481,483.14 |
PGC | Paragon Care Limited | 0.275 | 49 | 0 | $ 91,229,028.84 |
RGS | Regeneus Ltd | 0.075 | -4 | 0 | $ 23,068,915.59 |
PAR | Paradigm Bio. | 2.03 | -40 | 0 | $ 459,979,319.94 |
MVF | Monash IVF Group Ltd | 0.82 | 38 | -1 | $ 331,189,614.00 |
IMU | Imugene Limited | 0.3375 | 864 | -1 | $ 1,662,551,924.95 |
NOX | Noxopharm Limited | 0.67 | 219 | -1 | $ 198,872,991.63 |
VLS | Vita Life Sciences.. | 1.11 | 102 | -1 | $ 58,444,399.32 |
EZZ | EZZ Life Science | 0.46 | -8 | -1 | $ 5,520,000.00 |
ADO | Anteotech Ltd | 0.26 | 1138 | -2 | $ 497,925,453.18 |
S66 | Star Combo | 0.25 | -35 | -2 | $ 33,678,117.25 |
IHL | Incannex Healthcare | 0.245 | 308 | -2 | $ 265,083,190.00 |
ZNO | Zoono Group Ltd | 0.645 | -80 | -2 | $ 102,137,378.34 |
LBT | LBT Innovations | 0.081 | -57 | -2 | $ 25,442,134.43 |
BNO | Bionomics Limited | 0.195 | 273 | -3 | $ 196,481,365.08 |
CTE | Cryosite Limited | 0.39 | 200 | -3 | $ 18,275,229.57 |
CDX | Cardiex Limited | 0.073 | 170 | -3 | $ 71,304,937.94 |
GLH | Global Health Ltd | 0.51 | 143 | -3 | $ 25,259,323.35 |
RCE | Recce Pharmaceutical | 0.92 | 35 | -3 | $ 167,695,622.36 |
NXS | Next Science Limited | 1.505 | -3 | -3 | $ 312,798,776.22 |
RNO | Rhinomed Ltd | 0.15 | 100 | -3 | $ 38,071,369.80 |
RAC | Race Oncology Ltd | 3.58 | 348 | -3 | $ 517,143,034.80 |
CPH | Creso Pharma Ltd | 0.14 | 338 | -3 | $ 143,275,059.20 |
1AD | Adalta Limited | 0.135 | 14 | -4 | $ 34,325,140.92 |
RSH | Respiri Limited | 0.072 | -28 | -4 | $ 51,321,696.09 |
FFC | Farmaforce Ltd | 0.067 | 22 | -4 | $ 8,755,625.66 |
IDT | IDT Australia Ltd | 0.31 | 72 | -5 | $ 74,356,652.70 |
SHG | Singular Health | 0.3 | 50 | -5 | $ 18,574,729.42 |
IBX | Imagion Biosys Ltd | 0.095 | 111 | -5 | $ 98,010,503.33 |
PAL | Palla Pharma Ltd | 0.38 | -47 | -5 | $ 64,765,265.20 |
ICR | Intelicare Holdings | 0.18 | -51 | -5 | $ 8,685,866.74 |
MVP | Medical Developments | 4.44 | -38 | -5 | $ 319,265,730.56 |
IMM | Immutep Ltd | 0.53 | 221 | -5 | $ 407,743,349.58 |
SDI | SDI Limited | 0.88 | 27 | -5 | $ 105,790,321.70 |
RHY | Rhythm Biosciences | 0.865 | 941 | -6 | $ 181,953,729.90 |
BPH | BPH Energy Ltd | 0.075 | 380 | -6 | $ 48,539,115.40 |
ILA | Island Pharma | 0.3 | 20 | -6 | $ 12,238,802.31 |
OIL | Optiscan Imaging | 0.225 | 463 | -6 | $ 132,496,029.43 |
CYP | Cynata Therapeutics | 0.52 | -17 | -6 | $ 74,503,828.88 |
NC6 | Nanollose Limited | 0.089 | 117 | -6 | $ 13,381,773.12 |
PBP | Probiotec Limited | 2.04 | 3 | -6 | $ 160,065,348.24 |
OCC | Orthocell Limited | 0.57 | 65 | -7 | $ 104,821,283.05 |
JTL | Jayex Technology Ltd | 0.028 | 12 | -7 | $ 5,952,252.03 |
BWX | BWX Limited | 4.87 | 30 | -7 | $ 695,106,774.45 |
VBS | Vectus Biosystems | 1.3 | 91 | -8 | $ 41,152,012.20 |
MEM | Memphasys Ltd | 0.066 | 29 | -8 | $ 50,145,076.08 |
LSH | Lifespot Health Ltd | 0.1 | 119 | -9 | $ 16,846,695.70 |
PYC | PYC Therapeutics | 0.15 | 12 | -9 | $ 477,138,915.45 |
NSB | Neuroscientific | 0.325 | 41 | -11 | $ 45,193,567.55 |
PNV | Polynovo Limited | 2.465 | -4 | -11 | $ 1,587,331,305.60 |
HCT | Holista CollTech Ltd | 0.056 | -60 | -11 | $ 15,419,548.87 |
AMT | Allegra Orthopaedics | 0.22 | -58 | -12 | $ 22,981,024.66 |
ALC | Alcidion Group Ltd | 0.375 | 134 | -14 | $ 393,025,894.50 |
ONE | Oneview Healthcare | 0.39 | 942 | -21 | $ 164,488,796.14 |
ACW | Actinogen Medical | 0.105 | 329 | -32 | $ 190,964,232.91 |
CYC | Cyclopharm Limited | 1.645 | 10 | -39 | $ 156,869,702.64 |
LDX | Lumos Diagnostics | 1.3 | 4 | $ 190,693,564.51 |
Flat this fortnight was 1ST Group (ASX:1ST) – even after announcing a commitment to UN Sustainable Development Goals around digitally transforming healthcare (goal 3) and educating consumers to better manage their health (goal 4).
Cellmid Limited (ASX:CDY) couldn’t move the needle either, putting this down to significant retail disruption in 2H FY21. But the company assures stakeholders it plans to expand its foothold in Chinese markets, launch new ecommerce platforms in the US and Australian and increase Japanese sales growth in FY22.
And Medlab (ASX:MDC) was also flat, even though its NRGBiotic depression study with the Queensland University of Technology (QUT) showed notable mental health outcomes.
Cyclopharm (ASX:CYC) was the biggest loser, down 39% after US Food and Drug Administration (USFDA)unable to approve the new drug application (NDA) for its Technegas product for functional lung ventilation imaging.
The company has to address outstanding technical requirements within 12 months – and once completed – managing director James McBrayer said commercial sales in the US could commence in the second half of 2022.
On the right side of the FDA – but losing 32% was Actinogen (ASX:ACW) whose pre-investigational new drug application (Pre-IND) submission for its Fragile X syndrome (FXS) program was flagged as ‘sufficient’.
The full IND submission is planned in Q3 21, with the Phase II XanaFX 12-week trial investigating the safety and efficacy of Xanamem in male adolescents who suffer from FXS expected to begin in Q4.